Short Interest in BioNexus Gene Lab Corp. (NASDAQ:BGLC) Declines By 38.3%

BioNexus Gene Lab Corp. (NASDAQ:BGLC) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 17,038 shares, a decline of 38.3% from the December 31st total of 27,606 shares. Based on an average daily volume of 6,680 shares, the days-to-cover ratio is currently 2.6 days. Approximately 0.7% of the company’s shares are short sold. Approximately 0.7% of the company’s shares are short sold. Based on an average daily volume of 6,680 shares, the days-to-cover ratio is currently 2.6 days.

BioNexus Gene Lab Trading Down 4.0%

BGLC stock opened at $2.65 on Friday. The business’s fifty day moving average price is $3.94 and its 200 day moving average price is $4.83. BioNexus Gene Lab has a 12-month low of $2.01 and a 12-month high of $15.60. The company has a market capitalization of $6.25 million, a PE ratio of -3.49 and a beta of 5.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNexus Gene Lab in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.